These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Buechner J, Henriksen JR, Haug BH, Tømte E, Flaegstad T, Einvik C. Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091 [Abstract] [Full Text] [Related]
3. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Buechner J, Tømte E, Haug BH, Henriksen JR, Løkke C, Flægstad T, Einvik C. Br J Cancer; 2011 Jul 12; 105(2):296-303. PubMed ID: 21654684 [Abstract] [Full Text] [Related]
4. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES, Gunaratne PH. Cancer Res; 2011 Jun 01; 71(11):3841-51. PubMed ID: 21498633 [Abstract] [Full Text] [Related]
5. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. Int J Cancer; 2008 Feb 01; 122(3):699-704. PubMed ID: 17943719 [Abstract] [Full Text] [Related]
6. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B, Einvik C. Carcinogenesis; 2011 Jul 01; 32(7):1005-12. PubMed ID: 21572098 [Abstract] [Full Text] [Related]
7. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Chen Y, Stallings RL. Cancer Res; 2007 Feb 01; 67(3):976-83. PubMed ID: 17283129 [Abstract] [Full Text] [Related]
8. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, London WB, McGrady PW, Higgins DG, O'Meara A, O'Sullivan M, Stallings RL. PLoS One; 2009 Nov 16; 4(11):e7850. PubMed ID: 19924232 [Abstract] [Full Text] [Related]
9. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL. Mol Carcinog; 2011 Jun 16; 50(6):403-11. PubMed ID: 21557326 [Abstract] [Full Text] [Related]
10. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM. Cancer Res; 2003 Apr 01; 63(7):1631-5. PubMed ID: 12670915 [Abstract] [Full Text] [Related]
11. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, Djos A, Martinsson T, Christensen JG, Palmer RH, Hallberg B. Oncogene; 2012 Dec 13; 31(50):5193-200. PubMed ID: 22286764 [Abstract] [Full Text] [Related]
12. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, Beisel C, Gogolin S, Fischer M, Henrich KO, Ehemann V, Gillespie P, Schwab M, Westermann F. Cancer Res; 2010 May 01; 70(9):3791-802. PubMed ID: 20424123 [Abstract] [Full Text] [Related]
13. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. Cortés C, Kozma SC, Tauler A, Ambrosio S. Cell Oncol (Dordr); 2015 Oct 01; 38(5):341-52. PubMed ID: 26306783 [Abstract] [Full Text] [Related]
14. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, Kumps C, Schlierf S, De Preter K, Van Roy N, Noguera R, Laureys G, Schramm A, Eggert A, Westermann F, Speleman F, Vandesompele J. Oncogene; 2010 Mar 04; 29(9):1394-404. PubMed ID: 19946337 [Abstract] [Full Text] [Related]
15. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M. Proc Natl Acad Sci U S A; 2010 Jan 26; 107(4):1553-8. PubMed ID: 20080637 [Abstract] [Full Text] [Related]
16. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A, Köster J, Marschall T, Martin M, Schwermer M, Fielitz K, Büchel G, Barann M, Esser D, Rosenstiel P, Rahmann S, Eggert A, Schulte JH. Int J Cancer; 2013 Feb 01; 132(3):E106-15. PubMed ID: 22907398 [Abstract] [Full Text] [Related]
17. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Veas-Perez de Tudela M, Delgado-Esteban M, Cuende J, Bolaños JP, Almeida A. J Neurochem; 2010 May 01; 113(4):819-25. PubMed ID: 20180881 [Abstract] [Full Text] [Related]
18. Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, Flaegstad T, Einvik C. BMC Dev Biol; 2011 Jan 03; 11():1. PubMed ID: 21194500 [Abstract] [Full Text] [Related]
19. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M, Suenaga Y, Nakagawara A. Clin Cancer Res; 2011 Nov 01; 17(21):6681-92. PubMed ID: 21908575 [Abstract] [Full Text] [Related]